CellaVision AB
STO:CEVI
Net Margin
CellaVision AB
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SE |
|
CellaVision AB
STO:CEVI
|
4.5B SEK |
20%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
229.1B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
183.5B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
150.5B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
142.7B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.5B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
50.9B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
48.7B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
43.1B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
281.3B CNY |
31%
|
CellaVision AB
Glance View
CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. The company is headquartered in Lund, Skane and currently employs 200 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on CellaVision AB's most recent financial statements, the company has Net Margin of 20.3%.
You don't have any saved screeners yet